• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Infection . Call, chosen, HA 2 T 2, ANDC: validation of four severity scores in COVID-19 patients

tetano

Editor, Senior Moderator
Infection


. 2021 Nov 19.
doi: 10.1007/s15010-021-01728-0. Online ahead of print.
Call, chosen, HA [SUB]2[/SUB] T [SUB]2[/SUB], ANDC: validation of four severity scores in COVID-19 patients


Selina Wolfisberg[SUP] 1 [/SUP], Claudia Gregoriano[SUP] 1 [/SUP], Tristan Struja[SUP] 1 [/SUP], Alexander Kutz[SUP] 1 [/SUP], Daniel Koch[SUP] 1 [/SUP], Luca Bernasconi[SUP] 2 [/SUP], Angelika Hammerer-Lercher[SUP] 2 [/SUP], Christine Mohr[SUP] 3 [/SUP], Sebastian Haubitz[SUP] 1 3 [/SUP], Anna Conen[SUP] 1 3 [/SUP], Christoph A Fux[SUP] 1 3 [/SUP], Beat Mueller[SUP] 1 4 [/SUP], Philipp Schuetz[SUP] 5 6 [/SUP]



Affiliations

Abstract

Purpose: To externally validate four previously developed severity scores (i.e., CALL, CHOSEN, HA[SUB]2[/SUB]T[SUB]2[/SUB] and ANDC) in patients with COVID-19 hospitalised in a tertiary care centre in Switzerland.
Methods: This observational analysis included adult patients with a real-time reverse-transcription polymerase chain reaction or rapid-antigen test confirmed severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection hospitalised consecutively at the Cantonal Hospital Aarau from February to December 2020. The primary endpoint was all-cause in-hospital mortality. The secondary endpoint was disease progression, defined as needing invasive ventilation, ICU admission or death.
Results: From 399 patients (mean age 66.6 years ± 13.4 SD, 68% males), we had complete data for calculating the CALL, CHOSEN, HA[SUB]2[/SUB]T[SUB]2[/SUB] and ANDC scores in 297, 380, 151 and 124 cases, respectively. Odds ratios for all four scores showed significant associations with mortality. The discriminative power of the HA[SUB]2[/SUB]T[SUB]2[/SUB] score was higher compared to CALL, CHOSEN and ANDC scores [area under the curve (AUC) 0.78 vs. 0.65, 0.69 and 0.66, respectively]. Negative predictive values (NPV) for mortality were high, particularly for the CALL score (≥ 6 points: 100%, ≥ 9 points: 95%). For disease progression, discriminative power was lower, with the CHOSEN score showing the best performance (AUC 0.66).
Conclusion: In this external validation study, the four analysed scores had a lower performance compared to the original cohorts regarding prediction of mortality and disease progression. However, all scores were significantly associated with mortality and the NPV of the CALL and CHOSEN scores in particular allowed reliable identification of patients at low risk, making them suitable for outpatient management.

Keywords: COVID-19; Risk scores; Switzerland; Validation study.
 
Back
Top Bottom